Neovascular Glaucoma Follow-up

  • Author: Jacqueline Freudenthal, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Mar 9, 2011
 

Further Outpatient Care

  • Ophthalmologists should provide long-term follow-up care for patients with neovascular glaucoma (NVG), closely monitoring for any worsening in the patient's condition.
  • Intensity of follow-up care is related to the conditions predisposing the patient to the development of NVG (ie, CRVO, diabetic retinopathy).
Next

Complications

  • Complications include uncontrolled glaucoma, hyphema, and loss of vision.
Previous
Next

Prognosis

  • Generally, NVG carries a very guarded prognosis. Prognosis is highly dependent on the following 2 factors: prevention and treatment of NVG early in its course and the underlying disease process.
Previous
Next

Patient Education

Previous
 
Contributor Information and Disclosures
Author

Jacqueline Freudenthal, MD  Co-Investigator, Ophthalmic Consultants Centre, Toronto

Jacqueline Freudenthal, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, and Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Coauthor(s)

Yasser A Khan, MD  Consulting Staff, Credit Valley Eye Care

Yasser A Khan, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Iqbal Ike K Ahmed, MD, FRCSC  Clinical Assistant Professor, Department of Ophthalmology, University of Utah

Iqbal Ike K Ahmed, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Canadian Ophthalmological Society, and Ontario Medical Association

Disclosure: Nothing to disclose.

Khalid Hasanee, MD  Glaucoma and Anterior Segment Fellow, Department of Ophthalmology, University of Toronto

Khalid Hasanee, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, and Ontario Medical Association

Disclosure: Nothing to disclose.

Baseer U Khan, MD  Staff Physician, Department of Ophthalmology, University of Toronto, Canada

Baseer U Khan, MD is a member of the following medical societies: Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Bradford Shingleton, MD  Assistant Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary

Bradford Shingleton, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Martin B Wax, MD  Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc

Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Society for Neuroscience

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Matsui N, Kamao T, Azumi A. [Case of metastatic intraocular malignant lymphoma with neovascular glaucoma]. Nippon Ganka Gakkai Zasshi. Jul 2005;109(7):434-9. [Medline].

  2. Bellotti A, Labbe A, Fayol N, El Mahtoufi A, Baudouin C. [OCT and neovascular glaucoma]. J Fr Ophtalmol. Jun 2007;30(6):586-91. [Medline].

  3. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. Oct 1995;102(10):1434-44. [Medline].

  4. Hasanreisoglu M, Weinberger D, Mimouni K, Luski M, Bourla D, Kramer M, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. Jul-Aug 2009;19(4):607-12. [Medline].

  5. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. Nov 2007;18(6):502-8. [Medline].

  6. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2009;3.

  7. Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Arch Ophthalmol. Dec 2010;128(12):1539-45. [Medline].

  8. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. May 2008;28(5):696-702. [Medline].

  9. Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S. [Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review]. Arch Soc Esp Oftalmol. Oct 2008;83(10):579-88. [Medline].

  10. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. Sep 2008;115(9):1571-80, 1580.e1-3. [Medline].

  11. Lee SJ, Lee JJ, Kim SY, Kim SD. Intravitreal bevacizumab (Avastin) treatment of neovascular glaucoma in ocular ischemic syndrome. Korean J Ophthalmol. Jun 2009;23(2):132-4. [Medline].

  12. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. Feb 2011;129(2):145-50. [Medline].

  13. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. May 2009;147(5):912-8, 918.e1. [Medline].

  14. Luke J, Luke M, Grisanti S. [Antiangiogenic treatment for neovascular glaucoma and after filtering surgery]. Ophthalmologe. May 2009;106(5):407-12. [Medline].

  15. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol. May-Jun 2009;19(3):435-41. [Medline].

  16. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye (Lond). May 1 2009;[Medline].

  17. Eid TM, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol. Aug 2009;44(4):451-6. [Medline].

  18. Albert DM, Jakobiec FA. Neovascular glaucoma. Principles and Practice of Ophthalmology, Clinical Ophthalmology [book on CD-ROM]. Chapter 215.

  19. Browning DJ, Scott AQ, Peterson CB. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. May 1998;105(5):776-84. [Medline].

  20. Epstein DL, Allingham RR, Schuman JS. Chandler and Grant's Glaucoma. 4th ed. 1997:309-18.

  21. Gupta V, Agarwal HC. Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. Indian J Ophthalmol. Dec 2000;48(4):295-300. [Medline].

  22. Lieberman MF, Ewing RH. Drainage implant surgery for refractory glaucoma. Int Ophthalmol Clin. Summer 1990;30(3):198-208. [Medline].

  23. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. May 2009;93(5):589-93. [Medline].

  24. Muller VA, Ruokonen P, Schellenbeck M, et al. Treatment of rubeosis iridis with photodynamic therapy with verteporfin--A new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma?. Ophthalmic Res. Jan-Feb 2003;35(1):60-4. [Medline].

  25. Parodi MB, Iacono P. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am J Ophthalmol. Jul 2004;138(1):157-8. [Medline].

  26. Schlote T, Derse M, Rassmann K. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma. Aug 2001;10(4):294-301. [Medline].

  27. Shields MB. Textbook of Glaucoma. 4th ed. 1998:269-86.

  28. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. Oct 2001;108(10):1767-76; quiz1777, 1800. [Medline].

  29. Tripathi RC, Li J, Tripathi BJ. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. Feb 1998;105(2):232-7. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.